Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
about
Structure-Based Design, Synthesis, and Structure−Activity Relationship Studies of HIV-1 Protease Inhibitors Incorporating PhenyloxazolidinonesSubstrate Envelope-Designed Potent HIV-1 Protease Inhibitors to Avoid Drug ResistanceCurrent and Novel Inhibitors of HIV ProteaseA potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone.Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretroviralsHIV protease inhibitors: recent clinical trials and recommendations on use.Ritonavir-boosted protease inhibitors in HIV therapy.Cobicistat: a new boost for the treatment of human immunodeficiency virus infection.Baker's yeast as a tool for the development of antifungal drugs which target cell integrity - an update.Residual HIV-1 replication may impact immune recovery in patients on first-line lopinavir/ritonavir monotherapy.Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer.Human immunodeficiency virus protease inhibitors modulate Ca2+ homeostasis and potentiate alcoholic stress and injury in mice and primary mouse and human hepatocytes.Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity.Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study.Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.
P2860
Q27665164-3EC06F19-982F-4B1C-A94E-82EC5D540CDAQ27679880-C81DD45A-B54B-4CD9-A3B4-98D0DD55ED17Q35259915-F005DEFD-4274-4BAD-8D2D-59AB664137C3Q36741508-700A0D7B-2BA2-41C7-8639-FF564F8731E5Q36930446-CDB15B68-616B-4323-9D7B-4F0EBBF052B7Q37113947-68D10501-35F7-462A-B423-1048C0607F19Q37247615-D5F7823B-A0DE-4C92-97C5-20D12E513212Q37519715-B7169B7F-A915-43A2-BE9F-90A5879B70ECQ37866319-C921EEC3-B7C5-4799-BD0E-E0443BC6BF1DQ38087555-4061E33A-9D91-4861-AE8E-214FF67CD9D2Q38088803-C3FC4816-60F8-47A9-B5D3-9AD127D038C8Q38410752-69A8088B-9F10-4E93-809D-EC39C4073D7AQ39158102-2EC6ED8C-39B5-4217-B8E2-617AC4186391Q42037562-E7F4D1B9-793E-43E2-9A27-AEEEC97FEC1FQ43204477-6CC28899-8ADD-4884-8692-AFD5655B47BCQ44246520-6377E079-4496-4ED0-8BFC-E1BE9CAE0B61Q45919628-D5392CEB-8B17-4CA7-9D29-87245E943AC4
P2860
Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
@en
type
label
Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
@en
prefLabel
Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
@en
P356
P1476
Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
@en
P2093
Mike Youle
P304
P356
10.1093/JAC/DKM364
P407
P577
2007-09-21T00:00:00Z